OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

被引：1

作者：

Robson, Mark ^{[1
]}

Tutt, Andrew ^{[2
,3
]}

Balmana, Judith ^{[4
,13
]}

Kaufman, Bella ^{[5
]}

Garber, Judy ^{[6
]}

Geyer, Charles ^{[7
]}

Ford, James ^{[8
]}

Sharma, Priyanka ^{[9
]}

Stuart, Mary ^{[10
]}

Mann, Helen ^{[10
]}

Fasching, Peter A. ^{[11
,12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Kings Coll London, Sch Med, London WC2R 2LS, England

[3] Kings Coll London, Inst Canc Reseach, London WC2R 2LS, England

[4] Univ Hosp Vall dHebron, Barcelona, Spain

[5] Sheba Med Ctr, Tel Hashomer, Israel

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23284 USA

[8] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[9] Univ Kansas, Med Ctr, Lawrence, KS 66045 USA

[10] AstraZeneca, Bengaluru, Karnataka, India

[11] Univ Hosp, Newark, NJ USA

[12] German Breast Grp, Neu Isenburg, Germany

[13] SOLTI Breast Canc Res Grp, Barcelona, Spain

来源：

关键词：

D O I：

10.1158/1538-7445.SABCS14-OT1-1-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-1-04

引用

页数：2